On the other hand, other authors have been also reported that eleven pathogenic mutations have identified (3 in ATM, 1 in BRCA1, 2 in BRCA2, 1 in MLH1, 2 in MSH2, 1 in MSH6, and 1 in TP53) and that the prevalence of mutations was 3.8 %; the carrier status was associated significantly with breast cancer in the proband or first-degree relative, and with colorectal cancer in the proband or first-degree relative, but not family history of pancreatic cancer, age at diagnosis, or stage at diagnosis [21]. This evidence concerns the gene MSH2 and familial pancreatic carcinoma.